Cargando…

The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences

Biosimilars are cheaper than original drugs and are thus of interest to the public. The aim of this article is to assess the benefits of introducing more than one biosimilar for the same substance (active pharmaceutical ingredient, API). The hypothesis is that the introduction of successive biosimil...

Descripción completa

Detalles Bibliográficos
Autores principales: Barszczewska, Olga, Piechota, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297232/
https://www.ncbi.nlm.nih.gov/pubmed/34209612
http://dx.doi.org/10.3390/ijerph18136952
_version_ 1783725811622215680
author Barszczewska, Olga
Piechota, Anna
author_facet Barszczewska, Olga
Piechota, Anna
author_sort Barszczewska, Olga
collection PubMed
description Biosimilars are cheaper than original drugs and are thus of interest to the public. The aim of this article is to assess the benefits of introducing more than one biosimilar for the same substance (active pharmaceutical ingredient, API). The hypothesis is that the introduction of successive biosimilars of a specific original drug reduces the price of the selected API. The study focuses on drug prices varying with the successive arrival of new biosimilars. Three drugs that have at least three reimbursed biosimilars on the market were selected, two from the same therapeutic group (adalimumab and infliximab) and one (trastuzumab) representing another class of drugs. The following data were analyzed: price variation after the introduction of the first, second, and third biosimilar, and the average price reduction for all three biosimilars. Additionally, a literature review was conducted. The reimbursement of each new biosimilar is beneficial since it is associated with a price reduction in percentage terms. However, the first biosimilar brought about the greatest savings due to the higher initial prices of the original drugs and to Polish reimbursement rules. This article is helpful for when taking healthcare decisions regarding the pricing of and reimbursement for new biosimilars.
format Online
Article
Text
id pubmed-8297232
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82972322021-07-23 The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences Barszczewska, Olga Piechota, Anna Int J Environ Res Public Health Article Biosimilars are cheaper than original drugs and are thus of interest to the public. The aim of this article is to assess the benefits of introducing more than one biosimilar for the same substance (active pharmaceutical ingredient, API). The hypothesis is that the introduction of successive biosimilars of a specific original drug reduces the price of the selected API. The study focuses on drug prices varying with the successive arrival of new biosimilars. Three drugs that have at least three reimbursed biosimilars on the market were selected, two from the same therapeutic group (adalimumab and infliximab) and one (trastuzumab) representing another class of drugs. The following data were analyzed: price variation after the introduction of the first, second, and third biosimilar, and the average price reduction for all three biosimilars. Additionally, a literature review was conducted. The reimbursement of each new biosimilar is beneficial since it is associated with a price reduction in percentage terms. However, the first biosimilar brought about the greatest savings due to the higher initial prices of the original drugs and to Polish reimbursement rules. This article is helpful for when taking healthcare decisions regarding the pricing of and reimbursement for new biosimilars. MDPI 2021-06-29 /pmc/articles/PMC8297232/ /pubmed/34209612 http://dx.doi.org/10.3390/ijerph18136952 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Barszczewska, Olga
Piechota, Anna
The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences
title The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences
title_full The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences
title_fullStr The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences
title_full_unstemmed The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences
title_short The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences
title_sort impact of introducing successive biosimilars on changes in prices of adalimumab, infliximab, and trastuzumab—polish experiences
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297232/
https://www.ncbi.nlm.nih.gov/pubmed/34209612
http://dx.doi.org/10.3390/ijerph18136952
work_keys_str_mv AT barszczewskaolga theimpactofintroducingsuccessivebiosimilarsonchangesinpricesofadalimumabinfliximabandtrastuzumabpolishexperiences
AT piechotaanna theimpactofintroducingsuccessivebiosimilarsonchangesinpricesofadalimumabinfliximabandtrastuzumabpolishexperiences
AT barszczewskaolga impactofintroducingsuccessivebiosimilarsonchangesinpricesofadalimumabinfliximabandtrastuzumabpolishexperiences
AT piechotaanna impactofintroducingsuccessivebiosimilarsonchangesinpricesofadalimumabinfliximabandtrastuzumabpolishexperiences